Tag: Dynatronics Stock

  • Has Dynatronics (DYNT) Stock Risen This Session For A Reason?

    Shares of the leading manufacturer of athletic training, physical therapy, and rehabilitation products, Dynatronics Corporation (DYNT) were last checked at $1.38, up over 6.98% at mid of the session today. The DYNT stock closed at $1.29 last session. In the prior session, Dynatronics stock traded between $1.16 and $1.3799. DYNT stock has exchanged 24.84 million shares so far today, which is higher than the company’s 50-day daily volume of 0.7 million and its year-to-date volume of 1.2 million.

    DYNT’s performance:

    DYNT stock price has gone up 38.64% in the past 12 months, and 17.27% in the past week. DYNT stock is up 10.26% over six months, and by 5.74% over three months. Since the beginning of the year, DYNT stock has returned 59.26%.

    Since the DYNT stock fluctuated despite the absence of current news, recent developments may serve as valuable clues to its future.

    How did DYNT Stock do recently?

    Dynatronics is a leading manufacturer of health-improving medical devices. DYNT offers high-quality solutions that help patients achieve optimal health. In addition to developing and manufacturing clinical products, DYNT stock offers products for pain management, physical therapy, and performance enhancement.

    DYNT markets and sells its products through a variety of distribution channels, including orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and consumers. DYNT’s products are marketed under a range of well-known, high-quality brands, including Bird & Cronin, Dynatron Solaris, Hausmann, Physician’s Choice, and PROTEAM among others.

    In a recent announcement, Dynatronics promoted Sarah Rome-Mealman to Vice President of Marketing. In her 13 years of marketing and product innovation experience, Ms. Rome-Mealman has worked for companies including Rochester Medical, Teleflex, Medtronic, and Laborie/Cogentix Medical. She joined DYNT as Director of Product Marketing in September 2020 and has contributed considerably to the business transformation of the company.

    Her contribution to DYNT Stock growth:

    • During the early part of 2021, she led the launch of two differentiated new Hausmann table products targeted at higher-margin growth markets for DYNT.
    • Her contribution to DYNT’s “three brands, one company” rebranding has also been instrumental.
    • DYNT’s positive momentum in sales and margins is expected to be accelerated by her expertise in creating strategic marketing plans and leveraging relationships with new and existing dealers.
    • She has played a vital role in advancing DYNT’s Business and Product Portfolio Optimization strategic actions announced in April 2021 because of her ability to implement change quickly and efficiently.

    As a result:

    This is a well-deserved promotion, which Dynatronics (DYNT) sees as critical to establishing a foundation which supports accelerating growth in existing and adjacent markets. Ms. Rome-Mealman will continue to work out of DYNT’s pricipal executive office in Eagan, Minnesota.

  • Dynatronics Corporation (DYNT) stock popping high, what’s going on?

    Dynatronics Corporation (DYNT) stock popping high, what’s going on?

    The shares of Dynatronics Corporation (DYNT), a leading manufacturer of medical devices, are up about 85% in the current trading after the announcement made by the company that its wholly subsidiary, Bird & Cronin, LLC has renewed its purchasing agreement with Intalere, a leading purchasing organization in the healthcare industry, for Orthopedic Soft Goods and bracing.

    What’s Happening?

    The Extension of the key Distribution agreement is the main reason behind the rise of per-share price in pre-market trading. The per-share price was recorded to $2.36 with an 84.33% rise on the last check. According to the agreement

    • The partnership between Brid & Cronin and Intalere is extended to January 2024.
    • Intalere members will enjoy negotiated prices over a wide variety of bracing solutions for various upper and lower extremities.

    The 20-year long relationship between Bird & Cronin and Intalere has now been stronger as the former will help the latter through its bracing and support products to focus on the patients that would ultimately strengthen the internal and external infrastructure of Intalere.  

    In the second week of February, the company shared the second-quarter results in which the earnings per share decreased 20%, and a 21.25% decline in the revenue was observed.

    Conclusion:

    Currently, the DYNT stock is enjoying the bullish sentiment and captivating the attention of investors. With the expansion of its relationship with Intalere, there are chances that the stock will continue the uptrend in the future. In short, investors need to keep an eye on it.